sai-ying wang

sai-ying wang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2023 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SYSi Qi Yang
Si Qi Yang
YZYing Yong Zhou
Ying Yong Zhou
SYShu Ting Yang
Shu Ting Yang
XMXiao Yuan Mao
Xiao Yuan Mao
LCLiang Chen
Liang Chen
KDKaiming Duan
Kaiming Duan

13 October 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YZYing-Yong Zhou
Ying-Yong Zhou
SYShu-Ting Yang
Shu-Ting Yang
KDKai-Ming Duan
Kai-Ming Duan
ZBZhi-Hong Bai
Zhi-Hong Bai
YFYun-Fei Feng
Yun-Fei Feng
SWsai-ying wang
sai-ying wang
Background: With the development of fiberoptic bronchoscopy in the diagnosis and treatment of various pulmonary diseases, the anesthesia/sedation requirements are becoming more demanding, posing great challenges for patient safety while ensuring a smooth examination/surgery process. Remimazolam, a brand-new ultra-short-acting anesthetic, may compensate for the shortcomings of current anesthetic/sedation strategies in bronchoscopy.Methods: This study was a prospective, multicenter, randomized, double-blind, parallel positive controlled phase 3 clinical trial. Subjects were randomized to receive 0.2 mg/kg remimazolam besylate or 2 mg/kg propofol during bronchoscopy to evaluate the efficacy and safety of remimazolam.Results: A total of 154 subjects were successfully sedated in both the remimazolam group and the propofol group, with a success rate of 99.4% (95%CI of the adjusted difference −6.7 × 10%–6% to −5.1 × 10%–6%). The sedative effect of remimazolam was noninferior to that of propofol based on the prespecified noninferiority margin of −5%. Compared with the propofol group, the time of loss of consciousness in the remimazolam group (median 61 vs. 48s, p < 0.001), the time from the end of study drug administration to complete awakening (median 17.60 vs. 12.80 min, p < 0.001), the time from the end of bronchoscopy to complete awakening (median 11.00 vs. 7.00 min, p < 0.001), the time from the end of study drug administration to removal of monitoring (median 19.50 vs. 14.50 min, p < 0.001), and the time from the end of bronchoscopy to removal of monitoring (median 12.70 vs. 8.60 min, p < 0.001) were slightly longer. The incidence of Adverse Events in the remimazolam group and the propofol group (74.8% vs. 77.4%, p = 0.59) was not statistically significant, and none of them had Serious Adverse Events. The incidence of hypotension (13.5% vs. 29.7%, p < 0.001), hypotension requiring treatment (1.9% vs. 7.7%, p = 0.017), and injection pain (0.6% vs. 16.8%, p < 0.001) were significantly lower in the remimazolam group than in the propofol group.Conclusion: Moderate sedation with 0.2 mg/kg remimazolam besylate is effective and safe during bronchoscopy. The incidence of hypotension and injection pain was less than with propofol, but the time to loss of consciousness and recovery were slightly longer.Clinical Trial Registration:clinicaltrials.gov, ChiCTR2000039753


8 February 2023 in Journal of Affective Disorders
Verified
Journal Article
Closed access
HLHao Liu
Hao Liu
ADAnran Dai
Anran Dai
ZZZhou Zhou
Zhou Zhou
XXXiaowen Xu
Xiaowen Xu
KGKai Gao
Kai Gao
SWsai-ying wang
sai-ying wang

2 January 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
YZYingyong Zhou
Yingyong Zhou
ZBZhihong Bai
Zhihong Bai
WZWenchao Zhang
Wenchao Zhang
SXShouyu Xu
Shouyu Xu
YFYunfei Feng
Yunfei Feng
KDKaiming Duan
Kaiming Duan
Importance: Postpartum depression (PPD) is emerging as a major public health problem worldwide. Although the particular period and context in which PPD occurs provides an opportunity for preventive interventions, there is still a lack of pharmacologic prevention strategies for PPD.Objective: To assess the efficacy and safety of dexmedetomidine for prevention of PPD among women with prenatal depression undergoing cesarean delivery.Design, Setting, and Participants: This randomized clinical trial enrolled 338 women who screened positive for prenatal depression at 2 hospitals in Hunan, China from March 28, 2022, to April 16, 2023. Women with an Edinburgh Postnatal Depression Scale score of more than 9 who were 18 years of age or older and were scheduled for elective cesarean delivery were eligible.Interventions: Eligible participants were randomly assigned in a 1:1 ratio to either the dexmedetomidine group or the control group via centrally computer-generated group randomization. Dexmedetomidine, 0.5 μg/kg and 0.9% saline were intravenously infused for 10 minutes after delivery in the dexmedetomidine and control groups, respectively. After infusion, sufentanil or dexmedetomidine plus sufentanil was administered via patient-controlled intravenous analgesia for 48 hours in the control group and dexmedetomidine group, respectively.Main Outcomes and Measures: The primary outcome was positive PPD screening results at 7 and 42 days post partum, defined as a postpartum Edinburgh Postnatal Depression Scale score of more than 9. Analysis was on an intention-to-treat basis.Results: All 338 participants were female, with a mean (SD) age of 31.5 (4.1) years. Positive PPD screening incidence at 7 and 42 days post partum in the dexmedetomidine group vs the control group was significantly decreased (day 7, 21 of 167 [12.6%] vs 53 of 165 [32.1%]; risk ratio, 0.39 [95% CI, 0.25-0.62]; P < .001; day 42, 19 of 167 [11.4%] vs 50 of 165 [30.3%]; risk ratio, 0.38 [95% CI, 0.23-0.61]; P < .001). The dexmedetomidine group showed no significant difference in adverse events vs the control group (46 of 169 [27.2%] vs 33 of 169 [19.5%]; P = .10), but the incidence of hypotension increased (31 of 169 [18.3%] vs 16 of 169 [9.5%]; risk ratio, 2.15 [95% CI, 1.13-4.10]; P = .02).Conclusions and Relevance: Dexmedetomidine administration in the early postpartum period significantly reduced the incidence of a positive PPD screening and maintained a favorable safety profile.Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2200057213

18 August 2018 in Archives of Women's Mental Health
Verified
Journal Article
Closed access
PDF file
KDKaiming Duan
Kaiming Duan
SWsai-ying wang
sai-ying wang
JYJiye Yin
Jiye Yin
XLXi Li
Xi Li
JMJia-Hui Ma
Jia-Hui Ma
ZLZhao-Qian Liu
Zhao-Qian Liu